Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
IJPR-Iranian Journal of Pharmaceutical Research. 2005; 4 (4): 191-204
en Inglés | IMEMR | ID: emr-70891

RESUMEN

While drug toxicity [especially hepatotoxicity] is the most frequent reason cited for withdrawal of an approved drug, no simple solution exists to adequately predict such adverse events. Simple cytotoxicity assays in HepG2 cells are relatively insensitive to human hepatotoxic drugs in a retrospective analysis of marketed pharmaceuticals. In comparison, a panel of pre-lethal mechanistic cellular assays hold the promise to deliver a more sensitive approach to detect endpoint-specific drug toxicities. The panel of assays covered by this review includes steatosis, cholestasis, phospholipidosis, reactive intermediates, mitochondria membrane function, oxidative stress, and drug interactions. In addition, the use of metabolically competent cells or the introduction of major human hepatocytes in these in-vitro studies allow a more complete picture of potential drug side effect. Since inter-individual therapeutic index [TI] may differ from patient to patient, the rational use of one or more of these cellular assay and targeted in-vivo exposure data may allow pharmaceutical scientists to select drug candidates with a higher TI potential in the drug discovery phase


Asunto(s)
Preparaciones Farmacéuticas , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Hígado Graso , Colestasis , Fosfolípidos , Mitocondrias , Estrés Oxidativo , Interacciones Farmacológicas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA